Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that Company management will participate in the private company tracks of two upcoming investor conferences.
Piper Sandler Biopharma Symposium
1×1 Meetings: Wednesday, April 15, 2026
Location: Boston, MA
UBS Private Biotech Summit
1×1 Meetings: Monday, May 18, 2026
Location: New York, NY
About Ollin Biosciences
Established in 2023, Ollin BiosciencesTM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260408503553/en/
Media gallery
